{"id":15164,"date":"2023-09-07T10:34:17","date_gmt":"2023-09-07T08:34:17","guid":{"rendered":"https:\/\/www.bm-t.de\/?p=15164"},"modified":"2023-09-07T10:31:17","modified_gmt":"2023-09-07T08:31:17","slug":"grande-biotech-investiert-in-oncgnostics","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2023-en\/grande-biotech-investiert-in-oncgnostics\/","title":{"rendered":"Hong Kong firm invests in Jena-based Oncgnostics GmbH"},"content":{"rendered":"

The Hong Kong-based com\u00adpany Grande Bio-tech Co. Ltd. is mak\u00ading a 7\u2011digit Euros invest\u00adment in the Jena-based diag\u00adnos\u00adtic com\u00adpany Oncg\u00adnos\u00adtics GmbH<\/a>. Oncg\u00adnos\u00adtics has devel\u00adoped the can\u00adcer diag\u00adnos\u00adtic Gyn\u00adtect for the reli\u00adable detec\u00adtion of cer\u00advi\u00adcal can\u00adcer. Since 2022, this test has also been dis\u00adtrib\u00aduted and uti\u00adlized in col\u00adlab\u00ado\u00adra\u00adtion with a local part\u00adner in China. Fol\u00adlow\u00ading the suc\u00adcess\u00adful launch of Oncg\u00adnos\u00adtics\u2019 test in China, Grande Bio-tech Co. Ltd. has decided to make a finan\u00adcial com\u00admit\u00adment. The goal now is to expand the dis\u00adtri\u00adb\u00adu\u00adtion of tests devel\u00adoped by Oncg\u00adnos\u00adtics in the ASEAN countries.<\/strong><\/p>\n

ONCGNOSTICS IN CHINA SINCE 2022<\/h4>\n

After years of close col\u00adlab\u00ado\u00adra\u00adtion with a Chi\u00adnese part\u00adner, Oncg\u00adnos\u00adtics\u2019 Gyn\u00adtect test received approval for the Chi\u00adnese mar\u00adket in 2022. Since then, the test has been used in China under the name GongAnLi. The Hong Kong-based hold\u00ading Grande Bio-tech Co. Ltd., has now made a multi-mil\u00adlion-dol\u00adlar invest\u00adment. Dr. Alfred Hansel, Man\u00adag\u00ading Direc\u00adtor at Oncg\u00adnos\u00adtics and respon\u00adsi\u00adble for inter\u00adna\u00adtional busi\u00adness devel\u00adop\u00adment, stated, \u201cNot every med\u00adical prod\u00aduct receives approval for China. We\u2019ve suc\u00adceeded. Now the next step is expand\u00ading to whole Asia. Such suc\u00adcess is only pos\u00adsi\u00adble with strong part\u00adners.\u201d One of these part\u00adners is now Grande Bio-tech Co. Ltd., with Mr. Hu Mu as Man\u00adag\u00ading Direc\u00adtor, who men\u00adtioned, \u201cOncg\u00adnos\u00adtics is the right part\u00adner for us to take big steps in early can\u00adcer detection.\u201d<\/p>\n

BM\u2011T AND HTGF ENABLE MEGA-DEAL<\/h4>\n

Mr. Michael Thiele, Senior Invest\u00adment Man\u00adager at bm\u2011t beteili\u00adgungs\u00adman\u00adage\u00adment th\u00fcrin\u00adgen GmbH<\/a>, said: \u201cOncg\u00adnos\u00adtics is a prime exam\u00adple of Thuringia-based com\u00adpa\u00adnies oper\u00adat\u00ading at a global level. That\u2019s why we are fur\u00adther expand\u00ading our com\u00admit\u00adment into Oncg\u00adnos\u00adtics also with respect to pipeline prod\u00aduct devel\u00adop\u00adment.\u201d Dr. Bernd Goer\u00adgen, part\u00adner at HTGF, High-Tech Gr\u00fcn\u00adder\u00adfonds<\/a>, stated, \u201cAs an investor from the very begin\u00adning, we know the poten\u00adtial of Oncg\u00adnos\u00adtics\u2019 tech\u00adnol\u00adogy. There\u00adfore, we also par\u00adtic\u00adi\u00adpated in this financ\u00ading round.\u201d<\/p>\n

THE GYNTECT-TEST<\/h4>\n

Gyn\u00adtect is a swab test that accu\u00adrately deter\u00admines within a few hours whether there is a pre\u00adcan\u00adcer\u00adous con\u00addi\u00adtion or a tumor on the cervix. \u201cWith this test we are able to make quick and reli\u00adable assess\u00adments of a poten\u00adtial can\u00adcer con\u00addi\u00adtion. The usual months-long uncer\u00adtainty until fol\u00adlow-up exam\u00adi\u00adna\u00adtions is elim\u00adi\u00adnated,\u201d said Dr. Mar\u00adtina Schmitz, CEO and Sci\u00aden\u00adtific Direc\u00adtor of Oncg\u00adnos\u00adtics. At the same time, if there is an ele\u00advated can\u00adcer risk or can\u00adcer diag\u00adno\u00adsis, treat\u00adment can be ini\u00adti\u00adated more promptly. The test detects changes in the genetic mate\u00adr\u00adial of cells and does not require inva\u00adsive tis\u00adsue sampling.<\/p>\n

ABOUT ONCGNOSTICS<\/h4>\n

Oncg\u00adnos\u00adtics GmbH, a biotech startup spin off from the Jena Uni\u00adver\u00adsity Hos\u00adpi\u00adtal, devel\u00adops mol\u00ade\u00adc\u00adu\u00adlar biol\u00adogy tests for can\u00adcer diag\u00adnos\u00adtics based on epi\u00adge\u00adnetic changes in the human genome. With Gyn\u00adtect, the com\u00adpany intro\u00adduced an inno\u00adva\u00adtion in the field of cer\u00advi\u00adcal can\u00adcer screen\u00ading. Cur\u00adrently, the startup is devel\u00adop\u00ading fur\u00adther tests for head and neck can\u00adcers. The team of researchers led by founders Dr. Alfred Hansel (CEO) and Dr. Mar\u00adtina Schmitz (CSO) received the Thuringia Inno\u00adva\u00adtion Prize twice (2014, 2017) for their diag\u00adnos\u00adtic approach.<\/p>\n","protected":false},"excerpt":{"rendered":"

Hong Kong based Grande Bio-tech Co. Ltd. invests in cer\u00advi\u00adcal can\u00adcer diag\u00adnos\u00adtics com\u00adpany Oncg\u00adnos\u00adtics GmbH.<\/p>\n","protected":false},"author":2,"featured_media":15162,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[234],"tags":[210,159,171],"class_list":["post-15164","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-2023-en","tag-investeepartner","tag-investment-en","tag-thuringia"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=15164"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/15164\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media\/15162"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=15164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=15164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=15164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}